Future Proofing Cell & Gene Therapy: Strategies to Secure Your Leukapheresis Supply Chain

11

March

  • 3PM London / 11AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

Future-proofing cell and gene therapy requires more than innovation in the lab, it demands a resilient, access driven leukapheresis supply chain.  Strategic donor and patient engagement, integrated services, and adaptable infrastructure are essential to ensuring continuity, quality, and scalability from early development through commercialization.

Heather Munoz and Jimmy Johnson discuss today’s most persistent bottlenecks in sourcing well-qualified leukapheresis providers as part of autologous and allogeneic therapy supply chains, driven by constrained scheduling availability and a limited number of appropriate brick and mortar collection sites.  Emerging technologies and decentralized models, including the Mobile Leukapheresis Center, address the limitations of centralized collection sites by expanding geographic reach, reducing apheresis scheduling delays, and lowering non-medical logistical burdens for patients. By improving access to clinical trials, these approaches also strengthen clinical trial performance and commercial readiness through greater consistency, increased capacity, and faster access to patients.

A future proof supply chain is one built around access, flexibility, and mission driven collaboration.  Register for this impactful webinar and join the conversation.  BBG Advanced Therapies, where mission meets motion.

By the end of this webinar, participants will be able to:

  • Identify current challenges in leukapheresis collection sourcing, qualification, and scalability
  • Evaluate vendor qualification strategies that support long-term supply chain resilience
  • Assess the limitations of centralized collection centers in clinical and commercial settings
  • Describe how Mobile Leukapheresis Centers enable decentralized, flexible collection models
  • Understand the downstream impact of leukapheresis access on clinical trial timelines and commercialization

Speakers

Select a speaker to learn more

Back
Heather Munoz
Principal, Global Market Development

Heather Pariseau Munoz, MN, RN, CPN, CPHON, QIA, is an experienced nursing thought leader passionate about advancing access of cell and gene therapy through innovative apheresis and infusion care models. With a strong background in hematology/oncology and apheresis nursing, she combines clinical expertise with operational insight to support high-quality, patient-centered programs. As Principal of Global Market Development at BBG Advanced Therapies, her role focuses on expanding access to apheresis services and accelerating next-generation therapies. She is a certified apheresis specialist (QIA) and is deeply committed to mentorship, quality improvement, and driving meaningful impact with the evolving CGT landscape.

Next speaker
Back
James “Jimmy” Johnson
Director, Starting Materials and Research

James Johnson, MBA, is an experienced operational leader dedicated to advancing cell and gene therapy through high-quality apheresis and clinical research collection programs. With deep expertise in leukapheresis and cell-based collections, he combines operational leadership with donor-focused program design to ensure reliable, compliant starting materials for research and therapeutic development. His work centers on overseeing donor recruitment and screening, optimizing collection workflows, and fostering strong collaboration with research partners. James is committed to building dependable, well-run collection operations that support innovation and accelerate the progress of next-generation cell and gene therapy programs.

Next speaker
Back
Jack Cuthbertson
Senior Oncology and Hematology Analyst

Jack Cuthbertson, MSc, is a Senior Oncology and Hematology Analyst based in London, UK. His core responsibilities include providing in-depth analyses and market intelligence, as well as forecasting the markets of oncology indications, and covering high-profile oncology congresses. Jack has been part of the oncology and hematology team for more than two years. Prior to his current role, he was working on the development of non-viral DNA vectors for gene therapy and biopharmaceutical manufacturing. Jack has an MSc in Synthetic Biology and a BSc in Biochemistry from Newcastle University.

Next speaker

Enquiry